Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated at UBS Group

Stock analysts at UBS Group assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $38.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. Royal Bank of Canada cut their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Finally, HC Wainwright reduced their price objective on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $64.44.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $5.49 on Thursday. The firm has a 50-day moving average of $13.42 and a 200-day moving average of $17.70. Jasper Therapeutics has a one year low of $4.55 and a one year high of $31.01. The company has a market cap of $82.35 million, a P/E ratio of -1.16 and a beta of 2.11.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in JSPR. Russell Investments Group Ltd. increased its holdings in Jasper Therapeutics by 16.9% in the 4th quarter. Russell Investments Group Ltd. now owns 247,272 shares of the company’s stock worth $5,287,000 after acquiring an additional 35,746 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. Wellington Management Group LLP boosted its position in Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock worth $579,000 after purchasing an additional 3,310 shares during the period. Schroder Investment Management Group purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $1,237,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Jasper Therapeutics in the fourth quarter valued at approximately $223,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.